awmsg logo



fentanyl (Instanyl®)


Reference No. 584

Publication date:
01/06/2010


Appraisal information

fentanyl (Instanyl®) nasal spray


Company: Nycomed UK Ltd
BNF category: Central nervous system
NMG meeting date: 17/03/2010
AWMSG meeting date: 28/04/2010
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0710
Ministerial ratification: 28/05/2010

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fentanyl intranasal spray (Instanyl®) is recommended as an option for use within NHS Wales for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Fentanyl intranasal spray (Instanyl®) should only be considered as an option for the management of breakthrough cancer pain when immediate release oral opioids (e.g. morphine, oxycodone) are either inadequate or unsuitable. Fentanyl intranasal spray (Instanyl®) may be suitable for shared care but should be initiated by, and remain under the supervision of, a physician experienced in the management of opioid therapy in cancer patients.
Final Appraisal Recommendation (FAR)
Download